April 19 (Reuters) - Nicox SA NCOX.PA :
* NICOX PROVIDES FIRST QUARTER 2023 FINANCIAL AND BUSINESS
HIGHLIGHTS
* NET REVENUE OF EUR 0.8 MILLION FOR Q1 OF 2023
* CASH POSITION OF EUR 21.4 MILLION AS OF MARCH 31
* APPROVAL AND LAUNCH OF ZERVIATE IN CHINA BY OCUMENSION:
EXPECTED
IN 2024
* DENALI PHASE 3 CLINICAL TRIAL EVALUATING NCX 470 IN
PATIENTS
WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION: TOPLINE RESULTS
EXPECTED IN 2025
Source text for Eikon: ID:nGNX5c2tGV
Further company coverage: NCOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))